158 related articles for article (PubMed ID: 29195127)
21. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
[TBL] [Abstract][Full Text] [Related]
22. NK cell activity in the presence of IL-12 is a prognostic assay to neoadjuvant chemotherapy in cervical cancer.
Cosiski Marana HR; Santana da Silva J; Moreira de Andrade J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):318-23. PubMed ID: 10985887
[TBL] [Abstract][Full Text] [Related]
23. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.
Boerman GH; van Ostaijen-ten Dam MM; Kraal KC; Santos SJ; Ball LM; Lankester AC; Schilham MW; Egeler RM; van Tol MJ
Cancer Immunol Immunother; 2015 May; 64(5):573-83. PubMed ID: 25854581
[TBL] [Abstract][Full Text] [Related]
24. Lower concentrations of methyl-β-cyclodextrin combined with interleukin-2 can preferentially induce activation and proliferation of natural killer cells in human peripheral blood.
Lü HZ; Zhu AY; Chen Y; Tang J; Li BQ
Hum Immunol; 2011 Jul; 72(7):538-46. PubMed ID: 21540068
[TBL] [Abstract][Full Text] [Related]
25. Melatonin alleviates progression of uterine endometrial cancer by suppressing estrogen/ubiquitin C/SDHB-mediated succinate accumulation.
Gu C; Yang H; Chang K; Zhang B; Xie F; Ye J; Chang R; Qiu X; Wang Y; Qu Y; Wang J; Li M
Cancer Lett; 2020 Apr; 476():34-47. PubMed ID: 32061949
[TBL] [Abstract][Full Text] [Related]
26. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
Pope BL; Chourmouzis E; Sigindere J; MacIntyre JP; Capetola RJ; Lau CY
Cell Immunol; 1993 Apr; 147(2):302-12. PubMed ID: 8453674
[TBL] [Abstract][Full Text] [Related]
27. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
[TBL] [Abstract][Full Text] [Related]
28. Suppressive effect of a standardized mistletoe extract on the expression of activatory NK receptors and function of human NK cells.
Lee SJ; Son YO; Kim H; Kim JY; Park SW; Bae JH; Kim HH; Lee EY; Chung BS; Kim SH; Kang CD
J Clin Immunol; 2007 Sep; 27(5):477-85. PubMed ID: 17530391
[TBL] [Abstract][Full Text] [Related]
29. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
30. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.
Huenecke S; Zimmermann SY; Kloess S; Esser R; Brinkmann A; Tramsen L; Koenig M; Erben S; Seidl C; Tonn T; Eggert A; Schramm A; Bader P; Klingebiel T; Lehrnbecher T; Passweg JR; Soerensen J; Schwabe D; Koehl U
J Immunother; 2010; 33(2):200-10. PubMed ID: 20145545
[TBL] [Abstract][Full Text] [Related]
31. IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor.
Hyodo Y; Matsui K; Hayashi N; Tsutsui H; Kashiwamura S; Yamauchi H; Hiroishi K; Takeda K; Tagawa Y; Iwakura Y; Kayagaki N; Kurimoto M; Okamura H; Hada T; Yagita H; Akira S; Nakanishi K; Higashino K
J Immunol; 1999 Feb; 162(3):1662-8. PubMed ID: 9973427
[TBL] [Abstract][Full Text] [Related]
32. In vitro cytotoxicity and transplantation protection by autologous natural and activated killer cells against an in vitro transformed tumorigenic fibroblast line. A case study.
Wilhelm SA; Mukherji B
J Clin Invest; 1985 Apr; 75(4):1162-8. PubMed ID: 3988936
[TBL] [Abstract][Full Text] [Related]
33. Human anti-pig NK cell and CD8
Madelon N; Puga Yung GL; Seebach JD
Xenotransplantation; 2016 Nov; 23(6):479-489. PubMed ID: 27862343
[TBL] [Abstract][Full Text] [Related]
34. Natural killer activity in cloned cytotoxic T lymphocytes: regulation by interleukin 2, interferon, and specific antigen.
Brooks CG; Holscher M; Urdal D
J Immunol; 1985 Aug; 135(2):1145-52. PubMed ID: 2409140
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.
Yoshida N; Ino K; Ishida Y; Kajiyama H; Yamamoto E; Shibata K; Terauchi M; Nawa A; Akimoto H; Takikawa O; Isobe K; Kikkawa F
Clin Cancer Res; 2008 Nov; 14(22):7251-9. PubMed ID: 19010841
[TBL] [Abstract][Full Text] [Related]
36. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease.
Liu Z; Yang L; Cui Y; Wang X; Guo C; Huang Z; Kan Q; Liu Z; Liu Y
Inflamm Bowel Dis; 2009 Aug; 15(8):1133-44. PubMed ID: 19322899
[TBL] [Abstract][Full Text] [Related]
37. Adrenocorticotropin stimulates natural killer cell activity.
McGlone JJ; Lumpkin EA; Norman RL
Endocrinology; 1991 Sep; 129(3):1653-8. PubMed ID: 1651855
[TBL] [Abstract][Full Text] [Related]
38. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
39. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18.
Lauwerys BR; Renauld JC; Houssiau FA
Cytokine; 1999 Nov; 11(11):822-30. PubMed ID: 10547269
[TBL] [Abstract][Full Text] [Related]
40. Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells.
Chehimi J; Valiante NM; D'Andrea A; Rengaraju M; Rosado Z; Kobayashi M; Perussia B; Wolf SF; Starr SE; Trinchieri G
Eur J Immunol; 1993 Aug; 23(8):1826-30. PubMed ID: 8102101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
